NO972707L - Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon - Google Patents

Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon

Info

Publication number
NO972707L
NO972707L NO972707A NO972707A NO972707L NO 972707 L NO972707 L NO 972707L NO 972707 A NO972707 A NO 972707A NO 972707 A NO972707 A NO 972707A NO 972707 L NO972707 L NO 972707L
Authority
NO
Norway
Prior art keywords
receptor
opioid
modulating
compound
receptor function
Prior art date
Application number
NO972707A
Other languages
English (en)
Norwegian (no)
Other versions
NO972707D0 (no
Inventor
Olivier Civelli
James Richard Martin
Frederick Monsma
Jean-Luc Moreau
Hans-Peter Nothacker
Rainer Reinscheid
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO972707D0 publication Critical patent/NO972707D0/no
Publication of NO972707L publication Critical patent/NO972707L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO972707A 1996-06-13 1997-06-12 Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon NO972707L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96109462 1996-06-13

Publications (2)

Publication Number Publication Date
NO972707D0 NO972707D0 (no) 1997-06-12
NO972707L true NO972707L (no) 1997-12-15

Family

ID=8222893

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972707A NO972707L (no) 1996-06-13 1997-06-12 Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon

Country Status (17)

Country Link
US (2) US6326156B1 (ja)
JP (1) JP3212537B2 (ja)
KR (1) KR100247670B1 (ja)
CN (1) CN1184254A (ja)
AR (1) AR007548A1 (ja)
AU (1) AU719519B2 (ja)
BR (1) BR9703546A (ja)
CA (1) CA2206192A1 (ja)
CZ (1) CZ179597A3 (ja)
HU (1) HUP9701032A3 (ja)
IL (1) IL121017A0 (ja)
MX (1) MX9704352A (ja)
NO (1) NO972707L (ja)
NZ (1) NZ328033A (ja)
PL (1) PL320527A1 (ja)
TR (1) TR199700482A2 (ja)
ZA (1) ZA975077B (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100408556C (zh) * 2002-10-07 2008-08-06 加利福尼亚大学董事会 通过阻断花生四烯酰乙醇酰胺的水解调节焦虑
WO2008030752A2 (en) * 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
WO2008063714A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
EP2282742A1 (en) 2008-04-09 2011-02-16 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8546564B2 (en) 2009-04-07 2013-10-01 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8541581B2 (en) 2009-04-07 2013-09-24 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8927551B2 (en) * 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) * 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
MX361692B (es) 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
CA2843265C (en) 2010-07-28 2019-09-17 The Regents Of The University Of California Peripherally restricted faah inhibitors
EP2744778B1 (en) 2011-08-19 2019-01-16 The Regents of The University of California Meta-substituted biphenyl peripherally restricted faah inhibitors
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2015157313A1 (en) 2014-04-07 2015-10-15 The Regents Of The University Of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
CN114796446B (zh) * 2021-01-22 2024-08-30 宁夏杞肽科技有限公司 孤啡肽治疗氯胺酮成瘾的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3718317A1 (de) 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
EP0612845A3 (en) 1993-02-26 1994-09-21 American Cyanamid Co Purified opioid receptor.
US6096513A (en) 1993-05-20 2000-08-01 Arch Development Corporation Polynucleotides encoding KAPPA opiod receptors
US5658783A (en) * 1993-11-08 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Mammalian methadone-specific opioid receptor gene and uses
US5476933A (en) * 1994-11-16 1995-12-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Azepine synthesis via a diels-alder reaction
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
JP4191796B2 (ja) 1995-08-15 2008-12-03 ユーロスクリーン・ソシエテ・アノニム 拮抗剤または作動剤として、ヒトｏｒｌ１受容体に結合できることが知られていない化合物を回収する方法

Also Published As

Publication number Publication date
HUP9701032A2 (hu) 1998-08-28
KR100247670B1 (ko) 2000-06-01
HUP9701032A3 (en) 2000-04-28
AR007548A1 (es) 1999-11-10
ZA975077B (en) 1997-12-15
US20020082213A1 (en) 2002-06-27
JP3212537B2 (ja) 2001-09-25
CN1184254A (zh) 1998-06-10
AU719519B2 (en) 2000-05-11
US6326156B1 (en) 2001-12-04
CA2206192A1 (en) 1997-12-13
PL320527A1 (en) 1997-12-22
NO972707D0 (no) 1997-06-12
NZ328033A (en) 1998-11-25
TR199700482A2 (xx) 1998-01-21
AU2485397A (en) 1997-12-18
BR9703546A (pt) 1998-09-29
CZ179597A3 (cs) 1998-03-18
JPH1068724A (ja) 1998-03-10
IL121017A0 (en) 1997-11-20
MX9704352A (es) 1997-12-31
HU9701032D0 (en) 1997-07-28
KR980003586A (ko) 1998-03-30

Similar Documents

Publication Publication Date Title
NO972707L (no) Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon
AU3538195A (en) Assays and devices for the detection of extrahepatic biliary atresia
NZ306051A (en) Testing using electrochemiluminescence
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
DE69836888D1 (de) Verfahren für Fluoreszenzerkennungstest
TW347467B (en) Method and apparatus for testing an electrically conductive substrate
WO2000021987A3 (en) A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
WO2003069304A3 (en) Method and apparatus for assay of electrochemical properties
WO2003057029A8 (en) System and method of assessment of neurological conditions using eeg bispectrum
NO331148B1 (no) Anvendelse av et monoklonalt eller polyklonalt antistoff, samt fremgangsmate og kit for in vitro diagnose.
DE69936453D1 (de) Für einen g-protein gekoppelten rezeptor, der an der empfindungstransduktion beteiligt ist, kodierende nukleinsäuren
EP1055239B8 (en) Ultrasensitive surveillance of sensors and processes
CA2033168A1 (en) Method of Optical Analysis
EA200100899A1 (ru) ЦИТОЗОЛЬНАЯ ФОСФОЛИПАЗА A2 (cPLA2) И МОДЕЛЬ ЕЕ СТРУКТУРЫ, КРИСТАЛЛИЧЕСКАЯ КОМПОЗИЦИЯ, КОМПЬЮТЕРНАЯ СИСТЕМА, СПОСОБ ИДЕНТИФИКАЦИИ МОЛЕКУЛЫ И МОЛЕКУЛА, СПОСОБ ИДЕНТИФИКАЦИИ СУБСТАНЦИИ (ВАРИАНТЫ), СПОСОБ ИДЕНТИФИКАЦИИ ИНГИБИТОРОВ (ВАРИАНТЫ), АГОНИСТ ИЛИ АНТАГОНИСТ (ВАРИАНТЫ), СУБСТАНЦИЯ (ВАРИАНТЫ)
WO2002000933A3 (en) Screening assays for identifying modulators of the inflammatory or immune responses
CA2204305A1 (en) Apparatus and method for determination of urine color
AUPM411294A0 (en) Evaluation of signal processor performance
MX9606584A (es) Biosensores sensibles a masas.
MXPA03011898A (es) Ensayo de seleccion in vitro para ?- secretasa.
AU1305897A (en) Elisa test system
EP0813065A3 (en) Modulation of LC132 (opioid-like) receptor function
FR2783326B1 (fr) Procede de detection ou de quantification des basophiles et des eosinophiles
WO1998049292A3 (fr) Polypeptides associes a des recepteurs activateurs et leurs applications biologiques
EP0902273A3 (de) Verfahren und Vorrichtung zur quantitativen Bestimmung von Russ
AU6560096A (en) Homogeneous gene probe test using a receptor directed against the label

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application